Vaxxinity has selected VXX-401 to pursue as its anti-proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) vaccine candidate to treat hypercholesterolemia, and reported data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in nonhuman primates.